Fatty liver disease treatment based on seaweed nutraceuticals

Nutraceuticals made from certain seaweeds have been developed by the Central Marine
Fisheries Research Institute (CMFRI) in Kochi for the management of non-alcoholic fatty liver disease (NAFLD). Cadalmin LivCure extract is a proprietary combination of all-natural, seaweed-derived bioactive compounds designed to promote liver function.
The CMFRI, which is a part of the Indian Council of Agriculture Research, has created its ninth product using marine organisms (ICAR). The overarching group has previously released nutraceuticals to promote immunity and treat a wide range of lifestyle-related disorders such type-2 diabetes, arthritis, cholesterol, hypertension, hypothyroidism, and osteoporosis. Eight of these supplements come from seaweeds, while the last supplement comes from green mussels.
After extensive pre-clinical testing, the nutraceutical was shown to have no negative effects.
 Dr. Kajal Chakraborty, Principal Scientist at the Marine Biotechnology, Fish Nutrition and Health Division of the CMFRI, who led the research and issued the statement today, said that the findings "have proven that long-term oral administration of this product will not lead to general organ or systemic toxicity."
Soon, people in the pharmaceutical business who are interested in licencing the technology for commercial manufacturing of the nutraceutical will be able to do so.